Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Sch-23390. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 13/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.83 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.69 |
| ▸ | DRD5 | P21918 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | THPO | P40225 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | GPR183 | P32249 | 1/20 | 0.83 |
| ▸ | APLNR | P35414 | 1/20 | 0.83 |
| ▸ | GLP1R | P43220 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sch-23390 SCHEMBL9879320 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL11566592 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL11566584 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL7616595 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL461649 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL16187032 | 0.92 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL29797998 | 0.92 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL2916216 | 0.92 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL11107859 | 0.92 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 | |
| Sch-23390 SCHEMBL30628012 | 0.92 | DRD1 (1.00) | DRD1DRD2DRD5HSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058551-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 2000-12-13 | — | — | EP | claimed |
| WO-1999044615-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 1999-09-10 | — | — | WO | claimed |
| US-6410527-B1 | PSYCHOLOGICAL DISORDERS | SCHERING CORPORATION | 2002-06-25 | — | — | US | disclosed |
| EP-1058551-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE DISORDERS, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999044615-A1 | USE OF D1/D5 ANTAGONISTS FOR TREATING OBSESSIVE COMPULSIVE DISORDERS, SOMATOFORM DISORDERS, DISSOCIATIVE, EATING DISORDERS, IMPULSE CONTROL DISORDERS AND AUTISM | SCHERING CORPORATION (US) | 1999-09-10 | — | — | WO | disclosed |